JP2016520598A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520598A5 JP2016520598A5 JP2016515582A JP2016515582A JP2016520598A5 JP 2016520598 A5 JP2016520598 A5 JP 2016520598A5 JP 2016515582 A JP2016515582 A JP 2016515582A JP 2016515582 A JP2016515582 A JP 2016515582A JP 2016520598 A5 JP2016520598 A5 JP 2016520598A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- polypeptide
- acid modification
- heteromultimer
- hinge region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361829973P | 2013-05-31 | 2013-05-31 | |
| US61/829,973 | 2013-05-31 | ||
| PCT/CA2014/050507 WO2014190441A1 (en) | 2013-05-31 | 2014-05-30 | Heteromultimers with reduced or silenced effector function |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520598A JP2016520598A (ja) | 2016-07-14 |
| JP2016520598A5 true JP2016520598A5 (enExample) | 2017-06-22 |
| JP6567506B2 JP6567506B2 (ja) | 2019-08-28 |
Family
ID=51987817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515582A Expired - Fee Related JP6567506B2 (ja) | 2013-05-31 | 2014-05-30 | 低下した又はサイレント化したエフェクター機能を持つヘテロ多量体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11098105B2 (enExample) |
| EP (1) | EP3004174B1 (enExample) |
| JP (1) | JP6567506B2 (enExample) |
| KR (1) | KR102332303B1 (enExample) |
| CN (1) | CN105849129A (enExample) |
| AU (1) | AU2014273817B2 (enExample) |
| BR (1) | BR112015029788B1 (enExample) |
| CA (1) | CA2913370C (enExample) |
| DK (1) | DK3004174T3 (enExample) |
| ES (1) | ES2736326T3 (enExample) |
| RU (1) | RU2655439C2 (enExample) |
| WO (1) | WO2014190441A1 (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4793360A2 (en) | 2006-03-31 | 2026-08-19 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| TWI654203B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| CA2865158C (en) | 2012-02-24 | 2022-11-01 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib |
| BR112015000798A2 (pt) * | 2012-07-13 | 2017-06-27 | Zymeworks Inc | heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 |
| JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスＦｃγＲＩＩ特異的Ｆｃ抗体 |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| LT3074424T (lt) | 2013-11-27 | 2025-05-26 | Zymeworks Bc Inc. | Bispecifiniai antigeną surišantys konstruktai, nukreipti į her2 |
| FI3223848T3 (fi) | 2014-11-27 | 2025-02-28 | Zymeworks Bc Inc | Menetelmiä käyttää bispesifisiä antigeenia sitovia rakenteita, jotka kohdistuvat her2:een |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| CN114773469B (zh) | 2015-02-05 | 2025-12-19 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| MA45554A (fr) | 2016-07-01 | 2019-05-08 | Resolve Therapeutics Llc | Fusions de binucléase optimisées. |
| CN116271014A (zh) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| KR20240172236A (ko) | 2017-01-06 | 2024-12-09 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법 |
| TW201837174A (zh) | 2017-02-07 | 2018-10-16 | 日商第一三共股份有限公司 | 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子 |
| WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| MX2019013132A (es) * | 2017-05-25 | 2020-01-27 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas. |
| EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| US20200306301A1 (en) | 2017-07-03 | 2020-10-01 | Torque Therapeutics, Inc. | Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CN111315767B (zh) | 2017-08-22 | 2025-03-18 | 萨纳生物有限责任公司 | 可溶性干扰素受体及其用途 |
| CN118638787A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| AU2019235634A1 (en) | 2018-03-13 | 2020-10-22 | Zymeworks Bc Inc. | Anti-HER2 biparatopic antibody-drug conjugates and methods of use |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3765516A2 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| TWI827585B (zh) | 2018-03-15 | 2024-01-01 | 日商中外製藥股份有限公司 | 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法 |
| EP3807644A4 (en) * | 2018-06-12 | 2022-07-06 | Angiex, Inc. | ANTIBODY-OLIGONUCLEOTIDE CONJUGATES |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CN113330026A (zh) * | 2018-10-23 | 2021-08-31 | 美真达治疗公司 | Fc沉默的抗体药物缀合物(ADC)及其用途 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| SG11202109056TA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2020172598A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| SG11202109122SA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Anti-tcr antibody molecules and uses thereof |
| MX2021010254A (es) * | 2019-02-27 | 2021-09-21 | Angiex Inc | Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos. |
| WO2020219820A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| AU2020283890A1 (en) * | 2019-05-30 | 2021-12-16 | Amgen Inc. | Engineering the hinge region to drive antibody dimerization |
| EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CN115052663B (zh) | 2020-01-08 | 2026-06-09 | 辛瑟斯治疗股份有限公司 | Alk5抑制剂缀合物及其用途 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| TW202144572A (zh) | 2020-03-19 | 2021-12-01 | 美商亞維代堤生物科學公司 | 治療臉肩胛肱骨肌肉失養症之組合物及方法 |
| CA3175577A1 (en) | 2020-03-30 | 2021-10-07 | Mie University | Bispecific antibody |
| AU2021261420A1 (en) | 2020-04-24 | 2022-12-01 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CA3190573A1 (en) | 2020-08-26 | 2022-03-03 | Andreas Loew | Methods of detecting trbc1 or trbc2 |
| JP2023539645A (ja) | 2020-08-26 | 2023-09-15 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｎｋｐ３０に結合する抗体分子およびその使用 |
| AU2021331075A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| IL303967A (en) * | 2020-12-23 | 2023-08-01 | Immunowake Inc | Immunogenic cytokines and their uses |
| US11912781B2 (en) | 2021-01-13 | 2024-02-27 | Visterra, Inc. | Humanized complement 5A receptor 1 antibodies and methods of use thereof |
| CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
| EP4328243A4 (en) * | 2021-04-20 | 2025-05-21 | Korea University Research and Business Foundation | Asymmetric antibody with improved cytotoxicity against cancer cell |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| US12030945B2 (en) | 2022-10-25 | 2024-07-09 | Seismic Therapeutic, Inc. | Variant IgG Fc polypeptides and uses thereof |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
| WO2025064435A1 (en) * | 2023-09-19 | 2025-03-27 | Imaginab, Inc. | Antigen binding constructs directed to integrin αvβ6 |
| WO2026011013A1 (en) | 2024-07-02 | 2026-01-08 | Epibiologics, Inc. | Binding agents and uses thereof |
| WO2026037841A1 (en) | 2024-08-12 | 2026-02-19 | ONA Therapeutics S.L. | Anti-fgfr4 molecules and uses thereof |
| WO2026050572A2 (en) | 2024-08-29 | 2026-03-05 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
| US20260109746A1 (en) | 2024-10-22 | 2026-04-23 | Gilead Sciences, Inc. | Cd4-targeted il-15 molecules and methods of use |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7951917B1 (en) * | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| RU2325186C2 (ru) * | 2002-09-27 | 2008-05-27 | Ксенкор, Инк. | АНТИТЕЛО, СОДЕРЖАЩЕЕ Fc-ВАРИАНТНУЮ ЧАСТЬ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТИТЕЛО, И СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩЕГО |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
| PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
| EP1928495A2 (en) | 2005-08-19 | 2008-06-11 | Cerus Corporation | Antibody-mediated enhancement of immune response |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| CA3020928C (en) | 2008-05-15 | 2023-08-08 | National Research Council Of Canada | Expression systems encoding truncated ebna1, methods, and use thereof |
| EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| EP2504360B1 (en) * | 2009-11-23 | 2018-08-15 | Amgen Inc. | Monomeric antibody fc |
| CN102711810B (zh) | 2009-11-30 | 2015-04-22 | 詹森生物科技公司 | 效应子功能已消除的抗体Fc区突变体 |
| US20130108623A1 (en) | 2010-03-29 | 2013-05-02 | Zymeworks Inc | Antibodies with Enhanced or Suppressed Effector Function |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2011143545A1 (en) * | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| SG10201609665PA (en) * | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
| WO2012125850A1 (en) | 2011-03-16 | 2012-09-20 | Amgen Inc. | Fc variants |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| EP2698431B1 (en) * | 2011-03-30 | 2020-09-09 | Chugai Seiyaku Kabushiki Kaisha | Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity |
| WO2013002362A1 (ja) * | 2011-06-30 | 2013-01-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| WO2013012733A1 (en) * | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| US9562110B2 (en) | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| WO2014191746A1 (en) | 2013-05-31 | 2014-12-04 | Micromass Uk Limited | Compact mass spectrometer |
| BR112016000666A2 (pt) | 2013-07-12 | 2017-10-03 | Zymeworks Inc | Constructos de ligação de antígeno cd3 e cd19 biespecíficos |
-
2014
- 2014-05-30 EP EP14803370.7A patent/EP3004174B1/en active Active
- 2014-05-30 WO PCT/CA2014/050507 patent/WO2014190441A1/en not_active Ceased
- 2014-05-30 AU AU2014273817A patent/AU2014273817B2/en not_active Ceased
- 2014-05-30 JP JP2016515582A patent/JP6567506B2/ja not_active Expired - Fee Related
- 2014-05-30 CN CN201480039387.XA patent/CN105849129A/zh active Pending
- 2014-05-30 KR KR1020157036704A patent/KR102332303B1/ko active Active
- 2014-05-30 DK DK14803370.7T patent/DK3004174T3/da active
- 2014-05-30 RU RU2015152084A patent/RU2655439C2/ru active
- 2014-05-30 US US14/893,503 patent/US11098105B2/en active Active
- 2014-05-30 CA CA2913370A patent/CA2913370C/en active Active
- 2014-05-30 BR BR112015029788-9A patent/BR112015029788B1/pt not_active IP Right Cessation
- 2014-05-30 ES ES14803370T patent/ES2736326T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11739143B2 (en) | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same | |
| JP7178342B2 (ja) | アゴニズム及びエフェクター機能が増強した改変抗体、及び他のＦｃドメイン含有分子 | |
| CN114341186B (zh) | 双特异性抗LRRC15和CD3ε抗体 | |
| CN109715663B (zh) | 结合生长抑素受体2的异源二聚抗体 | |
| TW202227494A (zh) | 多特異性免疫靶向分子及其用途 | |
| JP2021019598A (ja) | Ｆｃ含有ポリペプチドの安定化 | |
| RU2015152084A (ru) | Гетеромультимеры с уменьшенной или подавленной эффекторной функцией | |
| JP2022033769A (ja) | 強化されたアゴニスト活性を有する、Ｆｃが遺伝子操作を受けた抗ＴＮＦＲスーパーファミリーメンバー抗体及びその使用方法 | |
| TW202231292A (zh) | 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法 | |
| TW202108618A (zh) | 用於調節t細胞介導之免疫的材料及方法 | |
| TW202233674A (zh) | 用於調節δγ鏈介導之免疫的組成物及方法 | |
| AU2019337394B2 (en) | Improved anti-FLT3 antigen binding proteins | |
| JP2022540620A (ja) | 胸腺間質性リンパ球新生因子（ｔｓｌｐ）受容体シグナル伝達に干渉する薬剤 | |
| WO2023051727A1 (zh) | 结合cd3的抗体及其用途 | |
| IL300930A (en) | Methods and compositions for the treatment of autoimmune diseases and cancer | |
| CN111465618A (zh) | 双特异性cd16-结合分子及其在疾病治疗中的用途 | |
| CN121057752A (zh) | 铰链经修饰的双特异性抗体 | |
| JP7822466B2 (ja) | 低減された凝集能及び低減された疎水性を有する、改善されたＦｃサイレンシングされた抗ｏｘＭＩＦ抗体 | |
| EP3623383A1 (en) | Improved bispecific flt3xcd3 antigen binding proteins | |
| TW202336035A (zh) | 治療自體免疫疾病及癌症之方法及組成物 | |
| WO2025201240A1 (en) | Antibodies targeting cd3, cd28, and pd-l1 and uses thereof | |
| WO2025133013A1 (en) | Anti-bacterial polypeptides | |
| WO2024188319A1 (zh) | 抗muc17、cd3和cd28三特异性抗体 | |
| HK40092434A (zh) | Btla抗体 | |
| EA040482B1 (ru) | Гуманизированное антитело для лечения или предотвращения когнитивных расстройств, способ его получения и агент для лечения или предотвращения когнитивных расстройств с его применением |